SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-045141
Filing Date
2024-05-20
Accepted
2024-05-20 15:43:18
Documents
57
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0206418-10q_osthera.htm   iXBRL 10-Q 653782
2 CERTIFICATION ea020641801ex31-1_osthera.htm EX-31.1 7303
3 CERTIFICATION ea020641801ex31-2_osthera.htm EX-31.2 7350
4 CERTIFICATION ea020641801ex32_osthera.htm EX-32 6023
  Complete submission text file 0001213900-24-045141.txt   4173182

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE osti-20240331.xsd EX-101.SCH 53721
6 XBRL CALCULATION FILE osti-20240331_cal.xml EX-101.CAL 20793
7 XBRL DEFINITION FILE osti-20240331_def.xml EX-101.DEF 210408
8 XBRL LABEL FILE osti-20240331_lab.xml EX-101.LAB 394582
9 XBRL PRESENTATION FILE osti-20240331_pre.xml EX-101.PRE 218684
61 EXTRACTED XBRL INSTANCE DOCUMENT ea0206418-10q_osthera_htm.xml XML 476326
Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Filer) CIK: 0001795091 (see all company filings)

IRS No.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 333-271034 | Film No.: 24964197
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)